QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the quarterly period ended | |
or | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the transition period from to | |
Commission File Number: | |
(Exact name of registrant as specified in its charter) |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
(Address of principal executive offices) | (Zip Code) | |
( | ||
(Registrant’s telephone number, including area code) | ||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||
Large accelerated filer | ☐ | Accelerated filer | ☐ | Smaller reporting company | |||
☒ | Emerging growth company |
Page | ||
PART I. | FINANCIAL INFORMATION | |
Item 1. | ||
Condensed Consolidated Income Statements for the three and nine months ended September 30, 2024 and 2023 (Unaudited) | ||
Condensed Consolidated Comprehensive Income Statements for the three and nine months ended September 30, | ||
2023 (Unaudited) | ||
Condensed Consolidated Statements of Changes in Equity for the three and nine months ended September | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
PART II. | OTHER INFORMATION | |
Item 1. | ||
Item 1A. | ||
Item 2. | ||
Item 3. | ||
Item 4. | ||
Item 5. | ||
Item 6. | ||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Total revenue | $ | $ | $ | $ | |||
Expenses: | |||||||
Salaries and benefits | |||||||
Professional fees | |||||||
Supplies | |||||||
Rents and leases | |||||||
Rents and leases, related party | |||||||
Other operating expenses | |||||||
Government stimulus income | ( | ||||||
Interest expense | |||||||
Depreciation and amortization | |||||||
Loss on extinguishment and modification of debt | |||||||
Other non-operating gains | ( | ( | ( | ||||
Total operating expenses | |||||||
Income before income taxes | |||||||
Income tax expense | |||||||
Net income | |||||||
Net income attributable to noncontrolling interests | |||||||
Net income attributable to Ardent Health Partners, Inc. | $ | $ | $ | $ | |||
Net income per share: | |||||||
Basic | $ | $ | $ | $ | |||
Diluted | $ | $ | $ | $ | |||
Weighted-average common shares outstanding: | |||||||
Basic | |||||||
Diluted |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Net income | $ | $ | $ | $ | |||
Other comprehensive (loss) income | |||||||
Change in fair value of interest rate swap | ( | ( | |||||
Other comprehensive (loss) income before income taxes | ( | ( | |||||
Income tax (benefit) expense related to other comprehensive (loss) income items | ( | ( | |||||
Other comprehensive (loss) income, net of income taxes | ( | ( | |||||
Comprehensive income | |||||||
Comprehensive income attributable to noncontrolling interests | |||||||
Comprehensive income attributable to Ardent Health Partners, Inc. | $ | $ | $ | $ |
September 30, 2024 (1) | December 31, 2023 (1) | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ | $ | |
Accounts receivable | |||
Inventories | |||
Prepaid expenses | |||
Other current assets | |||
Total current assets | |||
Property and equipment, net | |||
Operating lease right of use assets | |||
Operating lease right of use assets, related party | |||
Goodwill | |||
Other intangible assets, net | |||
Deferred income taxes | |||
Other assets | |||
Total assets | $ | $ | |
Liabilities and Equity | |||
Current liabilities: | |||
Current installments of long-term debt | $ | $ | |
Accounts payable | |||
Accrued salaries and benefits | |||
Other accrued expenses and liabilities | |||
Total current liabilities | |||
Long-term debt, less current installments | |||
Long-term operating lease liability | |||
Long-term operating lease liability, related party | |||
Self-insured liabilities | |||
Other long-term liabilities | |||
Total liabilities | |||
Commitments and contingencies (see Note 9) | |||
Redeemable noncontrolling interests | |||
Equity: | |||
Common units, respectively; respectively | |||
Preferred stock, par value $ December 31, 2023, respectively; 2023 | |||
Common stock, par value $ December 31, 2023, respectively; 142,735,842 and and December 31, 2023, respectively | |||
Additional paid-in capital | |||
Accumulated other comprehensive income | |||
Retained earnings | |||
Equity attributable to Ardent Health Partners, Inc. | |||
Noncontrolling interests | |||
Total equity | |||
Total liabilities and equity | $ | $ |
Nine Months Ended September 30, | |||
2024 | 2023 | ||
Cash flows from operating activities: | |||
Net income | $ | $ | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | |||
Other non-operating gains | ( | ||
Loss on extinguishment and modification of debt | |||
Amortization of deferred financing costs and debt discounts | |||
Deferred income taxes | |||
Equity-based compensation | |||
Loss from non-consolidated affiliates | |||
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures: | |||
Accounts receivable | ( | ||
Inventories | ( | ( | |
Prepaid expenses and other current assets | ( | ( | |
Accounts payable and other accrued expenses and liabilities | ( | ||
Accrued salaries and benefits | ( | ( | |
Net cash provided by operating activities | |||
Cash flows from investing activities: | |||
Investment in acquisitions, net of cash acquired | ( | ||
Purchases of property and equipment | ( | ( | |
Other | ( | ( | |
Net cash used in investing activities | ( | ( | |
Cash flows from financing activities: | |||
Proceeds from initial public offering, net of underwriting discounts and commissions | |||
Proceeds from insurance financing arrangements | |||
Proceeds from long-term debt | |||
Payments of principal on insurance financing arrangements | ( | ( | |
Payments of principal on long-term debt | ( | ( | |
Debt issuance costs | ( | ||
Payments of initial public offering costs | ( | ||
Distributions to noncontrolling interests | ( | ( | |
Redemption of equity attributable to noncontrolling interests | ( | ||
Other | ( | ||
Net cash provided by (used in) financing activities | ( | ||
Net increase (decrease) in cash and cash equivalents | ( | ||
Cash and cash equivalents at beginning of year | |||
Cash and cash equivalents at end of year | $ | $ | |
Supplemental Cash Flow Information: | |||
Non-cash purchases of property and equipment | $ | $ | |
Offering costs not yet paid | $ | $ |
Equity Attributable to Ardent Health Partners, Inc. | Noncontrolling Interests | Total Equity | |||||
Redeemable Noncontrolling Interests | Common Units | Accumulated Other Comprehensive Income | Retained Earnings | ||||
Units(*) | Amount | ||||||
Balance at December 31, 2022 | $ | $ | $ | $ | $ | $ | |
Net income attributable to Ardent Health Partners, Inc. | — | — | — | — | — | ||
Net income attributable to noncontrolling interests | — | — | — | — | — | ||
Net loss attributable to redeemable noncontrolling interests | ( | — | — | — | — | — | — |
Other comprehensive loss | — | — | — | ( | — | — | ( |
Distributions to noncontrolling interests | — | — | — | — | — | ( | ( |
Vesting of Class C Units | — | — | — | — | |||
Balance at March 31, 2023 | $ | $ | $ | $ | $ | $ | |
Net income attributable to Ardent Health Partners, Inc. | — | — | — | — | — | ||
Net income attributable to noncontrolling interests | — | — | — | — | — | ||
Net loss attributable to redeemable noncontrolling interests | ( | — | — | — | — | — | — |
Other comprehensive income | — | — | — | — | — | ||
Distributions to noncontrolling interests | — | — | — | — | — | ( | ( |
Redemption of equity attributable to noncontrolling interests | — | — | ( | — | — | ( | ( |
Vesting of Class C Units | — | — | — | — | |||
Balance at June 30, 2023 | $ | $ | $ | $ | $ | $ | |
Net income attributable to Ardent Health Partners, Inc. .. | — | — | — | — | — | ||
Net income attributable to noncontrolling interests ......... | — | — | — | — | — | ||
Net income attributable to redeemable noncontrolling interests .................................. | — | — | — | — | — | — | |
Other comprehensive income | — | — | — | — | — | ||
Distributions to noncontrolling interests ......... | — | — | — | — | — | ( | ( |
Vesting of Class C Units ....... | — | — | — | — | |||
Balance at September 30, 2023 .. | $ | $ | $ | $ | $ | $ |
Equity Attributable to Ardent Health Partners, Inc. | Non- controlling Interests | Total Equity | ||||||||
Redeemable Noncontrolling Interests | Common Units | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income | Retained Earnings | |||||
Units(*) | Amount | Shares | Amount | |||||||
Balance at December 31, 2023 | $ | $ | $ | $ | $ | $ | $ | $ | ||
Net income attributable to Ardent Health Partners, Inc. | — | — | — | — | — | — | — | — | ||
Net income attributable to noncontrolling interests | — | — | — | — | — | — | — | — | ||
Net loss attributable to redeemable noncontrolling interests | ( | — | — | — | — | — | — | — | — | — |
Other comprehensive income | — | — | — | — | — | — | — | — | ||
Distributions to noncontrolling interests | — | — | — | — | — | — | — | — | ( | ( |
Vesting of Class C Units | — | — | — | — | — | — | — | |||
Balance at March 31, 2024 | $ | $ | $ | $ | $ | $ | $ | $ | ||
Net income attributable to Ardent Health Partners, Inc. | — | — | — | — | — | — | — | — | ||
Net income attributable to noncontrolling interests | — | — | — | — | — | — | — | — | ||
Net loss attributable to redeemable noncontrolling interests | ( | — | — | — | — | — | — | — | — | — |
Other comprehensive loss | — | — | — | — | — | — | ( | — | — | ( |
Distributions to noncontrolling interests | — | — | — | — | — | — | — | — | ( | ( |
Vesting of Class C Units | — | — | — | — | — | — | — | |||
Balance at June 30, 2024 | $ | $ | $ | $ | $ | $ | $ | $ | ||
Net income attributable to Ardent Health Partners, Inc. | — | — | — | — | — | — | — | — | ||
Net income attributable to noncontrolling interests | — | — | — | — | — | — | — | — | ||
Net loss attributable to redeemable noncontrolling interests | ( | — | — | — | — | — | — | — | — | — |
Other comprehensive loss | — | — | — | — | — | — | ( | — | — | ( |
Issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions and other offering costs | — | — | — | — | — | — | ||||
Conversion of member units to common stock | — | ( | ( | — | — | ( | ||||
Distributions to noncontrolling interests | — | — | — | — | — | — | — | — | ( | ( |
Vesting of restricted stock unit awards | — | — | — | — | — | — | — | — | — | |
Tax withholding on vesting of restricted stock unit awards | — | — | — | ( | — | ( | — | — | — | ( |
Forfeiture of restricted stock awards | — | — | — | ( | — | — | — | — | — | — |
Equity-based compensation | — | — | — | — | — | — | — | — | ||
Balance at September 30, 2024 | $ | $ | $ | $ | $ | $ | $ | $ |
September 30, 2024 | December 31, 2023 | ||
Current liabilities | |||
Current installments of long-term debt | $ | $ | |
Accounts payable | |||
Accrued salaries and benefits | |||
Other accrued expenses and liabilities | |||
Total current liabilities | |||
Long-term debt, less current installments | |||
Long-term operating lease liability | |||
Long-term operating lease liability, related party | |||
Self-insured liabilities | |||
Other long-term liabilities | |||
Total liabilities | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Amount | % of Revenue | Amount | % of Revenue | Amount | % of Revenue | Amount | % of Revenue | ||||||||
Medicare | $ | $ | $ | $ | |||||||||||
Medicaid | |||||||||||||||
Other managed care | |||||||||||||||
Self-pay and other | |||||||||||||||
Net patient service revenue | $ | $ | $ | $ | |||||||||||
Other revenue | |||||||||||||||
Total revenue | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Oklahoma | |||||||
New Mexico | |||||||
Texas | |||||||
New Jersey | |||||||
Other | |||||||
Total |
Carrying Amount | Fair Value | ||||||
September 30, 2024 | December 31, 2023 | September 30, 2024 | December 31, 2023 | ||||
Senior Secured Term Loan Facility | $ | $ | $ | $ | |||
$ | $ | $ | $ |
September 30, 2024 | December 31, 2023 | ||
Senior secured term loan facility | $ | $ | |
Finance leases | |||
Other debt | |||
Deferred financing costs | ( | ( | |
Total debt | |||
Less current maturities | ( | ( | |
Long-term debt, less current maturities | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
Classification | 2024 | 2023 | 2024 | 2023 | ||||
Unrealized (loss) income recognized | AOCI | $( | $ | $ | $ | |||
Loss reclassified from AOCI into earnings | Interest expense, net | ( | ( | ( | ( | |||
Net change in AOCI | $( | $ | $( | $ |
Classification | September 30, 2024 | December 31, 2023 | |
Other current assets | $ | $ | |
Other assets | |||
Fair value | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Basic: | |||||||
Net income attributable to common stockholders | $ | $ | $ | $ | |||
Weighted-average number of common shares | |||||||
Net income per common share | $ | $ | $ | $ | |||
Diluted: | |||||||
Net income attributable to common stockholders | $ | $ | $ | $ | |||
Weighted-average number of common shares | |||||||
Net income per common share | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Weighted-average number of common shares - basic | |||||||
Effect of dilutive securities(1) | |||||||
Weighted-average number of common shares - diluted |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Medicare | 38.7% | 39.0% | 39.3% | 39.6% | |||
Medicaid | 10.2% | 11.0% | 10.6% | 11.3% | |||
Other managed care | 43.3% | 42.7% | 43.0% | 42.2% | |||
Self-pay and other | 5.5% | 5.5% | 5.2% | 5.1% | |||
Net patient service revenue | 97.7% | 98.2% | 98.1% | 98.2% | |||
Other revenue | 2.3% | 1.8% | 1.9% | 1.8% | |||
Total revenue | 100.0% | 100.0% | 100.0% | 100.0% |
Three Months Ended September 30, | |||||||
(Unaudited, dollars in thousands) | 2024 | 2023 | |||||
Amount | % | Amount | % | ||||
Total revenue | $1,449,817 | 100.0% | $1,377,727 | 100.0% | |||
Expenses: | |||||||
Salaries and benefits | 635,223 | 43.8% | 595,580 | 43.2% | |||
Professional fees | 274,223 | 18.9% | 246,540 | 17.9% | |||
Supplies | 251,862 | 17.4% | 249,548 | 18.1% | |||
Rents and leases | 26,410 | 1.8% | 24,506 | 1.8% | |||
Rents and leases, related party | 37,249 | 2.6% | 36,413 | 2.6% | |||
Other operating expenses | 117,700 | 8.2% | 124,642 | 9.1% | |||
Interest expense | 14,629 | 1.0% | 19,041 | 1.4% | |||
Depreciation and amortization | 36,771 | 2.5% | 35,488 | 2.6% | |||
Loss on extinguishment and modification of debt | 1,490 | 0.1% | — | 0.0% | |||
Other non-operating gains | (2,807) | (0.2)% | — | 0.0% | |||
Total operating expenses | 1,392,750 | 96.1% | 1,331,758 | 96.7% | |||
Income before income taxes | 57,067 | 3.9% | 45,969 | 3.3% | |||
Income tax expense | 11,062 | 0.7% | 7,261 | 0.5% | |||
Net income | 46,005 | 3.2% | 38,708 | 2.8% | |||
Net income attributable to noncontrolling interests | 19,683 | 1.4% | 17,870 | 1.3% | |||
Net income attributable to Ardent Health Partners, Inc. | $26,322 | 1.8% | $20,838 | 1.5% |
Nine Months Ended September 30, | |||||||
(Unaudited, dollars in thousands) | 2024 | 2023 | |||||
Amount | % | Amount | % | ||||
Total revenue | $4,359,783 | 100.0% | $4,063,449 | 100.0% | |||
Expenses: | |||||||
Salaries and benefits | 1,880,790 | 43.1% | 1,785,939 | 44.0% | |||
Professional fees | 810,820 | 18.6% | 715,111 | 17.6% | |||
Supplies | 769,034 | 17.6% | 743,713 | 18.3% | |||
Rents and leases | 76,251 | 1.7% | 73,230 | 1.8% | |||
Rents and leases, related party | 111,413 | 2.6% | 108,914 | 2.7% | |||
Other operating expenses | 354,851 | 8.2% | 342,026 | 8.3% | |||
Government stimulus income | — | 0.0% | (8,463) | (0.2)% | |||
Interest expense | 52,050 | 1.2% | 55,854 | 1.4% | |||
Depreciation and amortization | 108,434 | 2.5% | 104,860 | 2.6% | |||
Loss on extinguishment and modification of debt | 3,388 | 0.1% | — | 0.0% | |||
Other non-operating gains | (3,062) | (0.1)% | (522) | 0.0% | |||
Total operating expenses | 4,163,969 | 95.5% | 3,920,662 | 96.5% | |||
Income before income taxes | 195,814 | 4.5% | 142,787 | 3.5% | |||
Income tax expense | 36,997 | 0.9% | 24,591 | 0.6% | |||
Net income | 158,817 | 3.6% | 118,196 | 2.9% | |||
Net income attributable to noncontrolling interests | 62,678 | 1.4% | 60,139 | 1.5% | |||
Net income attributable to Ardent Health Partners, Inc. | $96,139 | 2.2% | $58,057 | 1.4% |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | % Change | 2023 | 2024 | % Change | 2023 | ||
Operating Statistics | |||||||
Total revenue (in thousands) | $1,449,817 | 5.2% | $1,377,727 | $4,359,783 | 7.3% | $4,063,449 | |
Hospitals operated (at period end) (1) | 30 | (3.2)% | 31 | 30 | (3.2)% | 31 | |
Licensed beds (at period end) (2) | 4,287 | (0.8)% | 4,323 | 4,287 | (0.8)% | 4,323 | |
Utilization of licensed beds (3) | 46% | 4.5% | 44% | 46% | 2.2% | 45% | |
Admissions (4) | 39,568 | 6.4% | 37,191 | 116,995 | 5.6% | 110,754 | |
Adjusted admissions (5) | 86,833 | 3.8% | 83,643 | 254,909 | 3.5% | 246,298 | |
Inpatient surgeries (6) | 8,871 | 0.5% | 8,826 | 26,829 | 0.3% | 26,751 | |
Outpatient surgeries (7) | 23,220 | 0.2% | 23,164 | 69,201 | (1.7)% | 70,417 | |
Emergency room visits (8) | 161,343 | 2.6% | 157,182 | 475,212 | 3.7% | 458,160 | |
Patient days (9) | 182,023 | 4.8% | 173,687 | 540,196 | 2.6% | 526,634 | |
Total encounters (10) | 1,482,655 | 7.5% | 1,378,599 | 4,304,097 | 4.7% | 4,109,144 | |
Average length of stay (11) | 4.60 | (1.5)% | 4.67 | 4.62 | (2.7)% | 4.75 | |
Net patient service revenue per adjusted admission (12) | $16,312 | 0.9% | $16,174 | $16,784 | 3.6% | $16,206 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
(in thousands) | 2024 | 2023 | 2024 | 2023 | |||
Net income | $46,005 | $38,708 | $158,817 | $118,196 | |||
Adjusted EBITDA Addbacks: | |||||||
Income tax expense | 11,062 | 7,261 | 36,997 | 24,591 | |||
Interest expense, net | 14,629 | 19,041 | 52,050 | 55,854 | |||
Depreciation and amortization | 36,771 | 35,488 | 108,434 | 104,860 | |||
Noncontrolling interest earnings | (19,683) | (17,870) | (62,678) | (60,139) | |||
Loss on extinguishment and modification of debt | 1,490 | — | 3,388 | — | |||
Other non-operating losses (gains) (a) | 47 | — | (208) | (522) | |||
Cybersecurity Incident recoveries, net (b) | (4,976) | — | (4,976) | — | |||
Restructuring, exit and acquisition-related costs (c) | 3,796 | 1,511 | 11,694 | 11,473 | |||
Epic expenses (d) | 485 | 437 | 1,500 | 1,415 | |||
Equity-based compensation | 8,135 | 181 | 8,873 | 723 | |||
Loss (income) from disposed operations | 3 | 3 | 1,989 | (65) | |||
Adjusted EBITDA | $97,764 | $84,760 | $315,880 | $256,386 |
Nine Months Ended September 30, | |||
2024 | 2023 | ||
Net cash provided by operating activities | $195,457 | $154,199 | |
Net cash used in investing activities | (115,016) | (81,277) | |
Net cash provided by (used in) financing activities | 45,124 | (84,370) |
Date (if redeemed during the 12 month period beginning on July 15 of the years indicated below) | Percentage |
2024 | 102.875% |
2025 | 101.438% |
2026 and thereafter | 100.000% |
Payments Due by Period | |||||
Total | Less than 1 Year | 1-3 Years | 3-5 Years | After 5 Years | |
Long-term debt obligations, with interest | $1,464,532 | $25,332 | $179,197 | $933,820 | $326,183 |
Deferred financing obligations, with interest | 15,449 | 2,601 | 11,456 | 1,392 | — |
Operating leases | 3,014,528 | 49,452 | 384,184 | 361,894 | 2,218,998 |
Estimated self-insurance liabilities | 185,073 | 40,976 | 39,439 | 61,618 | 43,040 |
Total | $4,679,582 | $118,361 | $614,276 | $1,358,724 | $2,588,221 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||
(in thousands) | 2024 | 2024 | |
Net income | $46,005 | $158,817 | |
Adjusted EBITDAR Addbacks: | |||
Income tax expense | 11,062 | 36,997 | |
Interest expense, net | 14,629 | 52,050 | |
Depreciation and amortization | 36,771 | 108,434 | |
Noncontrolling interest earnings | (19,683) | (62,678) | |
Loss on extinguishment and modification of debt | 1,490 | 3,388 | |
Other non-operating losses (gains) (a) | 47 | (208) | |
Cybersecurity Incident recoveries, net (b) | (4,976) | (4,976) | |
Restructuring, exit and acquisition-related costs (c) | 3,796 | 11,694 | |
Epic expenses (d) | 485 | 1,500 | |
Equity-based compensation | 8,135 | 8,873 | |
Loss from disposed operations | 3 | 1,989 | |
Rent expense payable to REITs (e) | 40,056 | 119,826 | |
Adjusted EBITDAR | $137,820 | $435,706 |
Exhibit Number | Description | |
2.1 | ||
3.1 | ||
3.2 | ||
4.1 | ||
10.1† | ||
10.2† | ||
10.3† | ||
10.4† | ||
10.5† | ||
10.6† | ||
10.7†# | ||
10.8 | ||
10.9† | ||
10.10† | ||
10.11 | ||
10.12 | ||
10.13 | ||
10.14* | ||
31.1* | ||
31.2* | ||
32.1** | ||
32.2** | ||
101.INS* | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
Exhibit Number | Description | |
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
# Portions of this exhibit (indicated by “[***]”) have been omitted as the registrant has determined that (i) the omitted information is not material and (ii) the omitted information is the type that the registrant treats as private or confidential. |
† Indicates a management contract or compensatory plan, contract or arrangement |
* Filed herewith |
** This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. |
ARDENT HEALTH PARTNERS, INC. | |||||
Date: November 7, 2024 | By: | /s/ Alfred Lumsdaine | ||
Alfred Lumsdaine | ||||
Executive Vice President, Chief Financial Officer | ||||
(Principal Financial Officer) |